There are currently 54 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Systemic Lupus Erythematosus participants are California, Florida, Texas and New York.
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Recruiting
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications... Read More
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
04/05/2024
Locations: Northwestern University, Chicago, Illinois +9 locations
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving placebo infusion plus standard of care.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/29/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +8 locations
Conditions: Systemic Lupus Erythematosus
Safety of the Herpes Zoster Subunit Vaccine in Lupus
Recruiting
This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
02/16/2024
Locations: NYU Langone Health, New York, New York +1 locations
Conditions: Systemic Lupus Erythematosus
Centrally Acting ACE Inhibition in SLE
Recruiting
SLE is a chronic autoimmune disease that often involves multiple systems and organs of the body. An autoimmune disease is one which your immune system attacks the cells and tissues in different parts of the body. SLE is characterized by inflammation that leads to tissue damage in many different organ systems. Lupus can cause fever, joint pains, rashes, and other symptoms. It can also affect organs such as the skin, the muscles, the kidneys, the heart, the lungs, the blood and the brain. The exac... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/09/2024
Locations: Yale University School of Medicine, New Haven, Connecticut +6 locations
Conditions: Systemic Lupus Erythematosus
Rheumatology Patient Registry and Biorepository
Recruiting
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
12/21/2023
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of CUG252 following multiple ascending doses in participants with Systemic Lupus Erythematosus (SLE).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/10/2023
Locations: Site 1001, Anniston, Alabama +10 locations
Conditions: Systemic Lupus Erythematosus, SLE (Systemic Lupus), Autoimmune